Immunome (NASDAQ:IMNM) Director Philip Wagenheim Sells 28,200 Shares

Key Points

• Director Philip Wagenheim sold 28,200 shares on March 23 at an average price of $20.65 for $582,330 and had sold 36,800 shares on March 20 at $20.47, leaving him with 341,147 shares (a 7.64% reduction) valued at about $7.04M.
• Shares traded up 3.7% to $20.75 with a market cap of roughly $2.35B and a 12-month range of $5.15–$27.65, while the company reported an EPS loss of $0.75, missing estimates and showing negative margins and return on equity.
• Analyst sentiment is largely positive—ten Buys and one Sell—with an average rating of "Moderate Buy" and an average price target of $33.45, including several firms raising targets into the $35–$40 range.

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Philip Wagenheim sold 28,200 shares of the business's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $20.65, for a total value of $582,330.00. Following the sale, the director directly owned 341,147 shares in the company, valued at $7,044,685.55. This trade represents a 7.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Philip Wagenheim also recently made the following trade(s):

• On Friday, March 20th, Philip Wagenheim sold 36,800 shares of Immunome stock. The stock was sold at an average price of $20.47, for a total transaction of $753,296.00.

Immunome Trading Up 3.7%

Shares of NASDAQ IMNM traded up $0.74 during trading on Monday, reaching $20.75. The company had a trading volume of 1,220,647 shares, compared to its average volume of 1,315,932. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $27.65. The stock has a market capitalization of $2.35 billion, a PE ratio of -8.57 and a beta of 2.12. The stock has a 50-day moving average price of $22.76 and a two-hundred day moving average price of $18.64.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. On average, sell-side analysts predict that Immunome, Inc. will post -2.21 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Guggenheim boosted their target price on Immunome from $25.00 to $35.00 and gave the stock a "buy" rating in a report on Tuesday, December 16th. Evercore raised their price target on shares of Immunome from $18.00 to $40.00 and gave the company an "outperform" rating in a report on Tuesday, December 16th. Leerink Partners set a $40.00 price target on shares of Immunome in a research report on Monday, December 15th. Truist Financial assumed coverage on shares of Immunome in a research report on Monday, December 1st. They issued a "buy" rating and a $36.00 price objective for the company. Finally, Stephens cut their target price on shares of Immunome from $33.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 4th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Immunome has an average rating of "Moderate Buy" and an average price target of $33.45.

Institutional Investors Weigh In On Immunome

Institutional investors and hedge funds have recently modified their holdings of the stock. Assetmark Inc. purchased a new stake in Immunome during the 3rd quarter worth approximately $39,000. BNP Paribas Financial Markets boosted its stake in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock valued at $60,000 after buying an additional 2,909 shares during the last quarter. Strs Ohio acquired a new stake in shares of Immunome during the fourth quarter worth approximately $64,000. Tower Research Capital LLC TRC grew its position in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after buying an additional 3,802 shares in the last quarter. Finally, BIT Capital GmbH bought a new stake in shares of Immunome in the third quarter worth $69,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.